Business
Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference
LEIDEN, Netherlands, January 08, 2026--Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15.
About this update from Jp Morgan Chase & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":270,"url":"https://media.zenfs.com/en/business-wire.com/02b18bedea86db06fbe5b0100735c79a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/g7OgjfC6BMTk_6JEt3N5sA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/02b18bedea86db06fbe5b0100735c79a","width":480,"height":270}},"lazy":false},{"type":"text","content":"LEIDEN, Netherlands, January 08, 2026--(BUSINESS WIRE)--Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15.","length":310,"tagName":"p"},{"type":"text","content":"The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET.","length":76,"tagName":"p"},{"type":"text","content":"The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC).","length":235,"tagName":"p"},{"type":"text","content":"Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025.","length":414,"tagName":"p"},{"type":"text","content":"About nizubaglustat","length":19,"tagName":"p"},{"type":"text","content":"Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick type C disease (NPC).","length":294,"tagName":"p"},{"type":"text","content":"Nizubaglustat has received Rare Pediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC, Orphan Drug Designations (ODD) for GM1 and GM2 ganglios...